Boehringer Ingelheim’s Post

🚨New Study Alert! 🚨 Unraveling the mysteries of liver health: "Four hepatic steatosis indices in predicting quantitative computed tomography-based metabolic dysfunction-associated fatty liver disease" is published! 🔍Discover how our latest research delves into non-invasive predictors of a growing health concern. Are hepatic steatosis indices the key to early detection and intervention? 👉Stay ahead in the field of hepatology by reading & downloading the full article now! 👉Scan the QR code or click the link below for direct access: https://lnkd.in/g4Njza9r After reading, don't forget to share your thoughts and the article within your network. Together, we can raise awareness and drive progress against metabolic dysfunction. #HepaticSteatosis #LiverHealth #FattyLiverDisease #MetabolicDysfunction #MedicalResearch #ShareTheKnowledge

We're especially thrilled to share the GLORY-1 Phase 3 study results of liver fat content in Chinese adults with overweight or obesity at the #ADA Scientific Sessions 2024. This clinical trial of mazdutide brings us closer to offering improved treatment options for those with metabolic dysfunction-associated steatohepatitis (MASH) and metabolic dysfunction-associated fatty liver disease (MAFLD). https://lnkd.in/gdXTAxKp

Half of Abnormal Liver Tests Point to Treatable Fatty Liver Disease: New AI Tool Assists Doctors The intelligent Liver Function Testing (iLFT) platform analyzes standard liver function tests and recommends further testing or suggests if a patient can be safely managed by their PCP. Fascinating, right? * 68% of patients using iLFT required further testing after their initial liver function test. * The most common finding was isolated abnormal alanine transaminase (ALT), often linked to fatty liver disease. * Half of the additional tests provided a cause for the liver dysfunction. * iLFT helped reduce unnecessary referrals to specialists by 34%. * More research is needed to refine the platform and optimize cost-effectiveness. iLFT has the potential to improve liver disease diagnosis and care, especially for fatty liver disease, a major health concern. #liverhealth #fattyliver #aihealthcare #primarycare #medicalinnovation #chronicillness #hepatitis #cirrhosis #medicaltechnology

Lipopolysaccharide (LPS) is the primary structural component of the outer membrane of most gram-negative bacteria, serving as a protective barrier. However, high levels of circulating cytokines can have damaging effects, leading to chronic systemic conditions. Type II diabetes, rheumatoid arthritis, Alzheimer’s disease, Parkinson’s disease, gastrointestinal disorders (including increased permeability), cardiovascular disease, metabolic disorders, autoimmunity, and other chronic inflammatory disorders have been linked to elevations of LPS. In the clinical environment, the endotoxin LPS remains challenging and difficult to manage. In this webinar, Dr. Bump describes the pathophysiology of LPS and reviews its structure, its mode of action, and why and how it becomes so toxic. He also reviews testing and describes therapeutic strategies for reducing LPS in overloaded patients. https://bit.ly/3QYMbCm #Bacteria #GutHealth #Autoimmunity #ChronicInflammatory #DrBump #DrChristopherBump #IntegratedHealthCare #VernonNJ #NJDoctors #FunctionalMedicine #LiveWell #InvestInYourself

Anthocyanin Effects on Vascular and Endothelial Health: Evidence from Clinical Trials and Role of Gut Microbiota Metabolites Laudani et al. (2023) Hypertension and derived cardiovascular disease (CVD) are among the leading causes of death worldwide. Increased oxidative stress and inflammatory state are involved in different alterations in endothelial functions that contribute to the onset of CVD. Polyphenols, and in particular anthocyanins, have aroused great interest for their antioxidant effects and their cardioprotective role. However, anthocyanins are rarely detected in blood serum because they are primarily metabolized by the gut microbiota.

#GLP1RA #semaglutide Long-term effects of semaglutide on weight in obesity without diabetes in the SELECT trial In the SELECT cardiovascular outcomes trial, semaglutide showed a 20% reduction in major adverse cardiovascular events in 17,604 adults with preexisting cardiovascular disease, overweight or obesity, without diabetes. In this prespecified analysis, authors examined effects of semaglutide on weight and anthropometric outcomes, safety and tolerability. In patients treated with semaglutide, weight loss continued over 65 weeks and was sustained for up to 4 years. At 208 weeks, semaglutide was associated with mean reduction  ▫️in weight −10.2% ▫️waist circumference −7.7 cm and  ▫️waist-to-height ratio −6.9% versus placebo Clinically meaningful weight loss occurred in both sexes and all races, body sizes and regions. Weight loss was sustained over 4 years. Semaglutide was associated with fewer serious adverse events. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial (https://lnkd.in/ePWHdsTE), Nature Medicine, 05.2024

"#Hypertension (high blood pressure) affects approximately one-third of adults and is a major risk factor for cardiovascular diseases, renal diseases and dementia, creating enormous health and economic burdens globally. The #Kidney controls blood pressure by regulating fluid and electrolyte homeostasis. Integral to this process is the NCC, a sodium–chloride cotransporter, which has a major role in fine-tuning urinary Na+ and Cl− excretion, regulating ion and acid–base balance, and controlling #BloodPressure! Decreased activity of the NCC underlies #GitelmanSyndrome, while increased activity of the NCC underlies #PseudoHypoAldosteronism Type II. Thus, the NCC is a prime #DrugTarget of pharmacological therapies for #Renal and #Cardiovascular disorders, including thiazide #Diuretics! Thiazide diuretics were the first oral antihypertensive #Drugs with decent #Efficacy and safety and remain the preferred first-line antihypertensive drugs. Despite being among the most widely prescribed drugs, the #MechanismOfAction (MoA) of thiazide diuretics selectively inhibition of and electroneutral transport of Na+ and Cl− via NCC remains elusive!" Do not miss this amazing article published in the Nature Magazine in which Liang Feng and colleagues from Stanford University School of Medicine determined the #CryoEM structures of human NCC alone and in complex with a commonly used thiazide diuretic: https://lnkd.in/eBigan2i These structures, together with functional studies, reveal major conformational states of the NCC and an intriguing regulatory MoA. They also illuminate how thiazide diuretics specifically interact with the NCC and inhibit its #Transport function! Overall, these results provide critical insights for understanding the Na–Cl cotransport mechanism of the NCC, and they establish a framework for future #DrugDesign and #DrugDevelopment as well as for interpreting disease-related mutations! If you are interested in how Cryo-EM is revolutionizing #DrugDiscovery, please follow this weblink to gain some deeper insights from there: https://lnkd.in/eXW7K_U6

Exploring Terminology Changes in Liver Health: NAFLD to MAFLD There's been a significant shift in the medical field from NAFLD (Non-Alcoholic Fatty Liver Disease) to MAFLD (Metabolic Associated Fatty Liver Disease). This change aims to better reflect the metabolic factors at play rather than just the absence of alcohol. At Arrow Dx, we understand the importance of clear terminology in advancing liver disease research and treatment. While this name change emphasizes underlying causes, we must consider its broad implications for disease awareness and treatment development. As leaders in liver disease detection technology, Arrow Dx remains committed to contributing to this vital dialogue. Stay updated with us on the latest in liver health. #LiverHealth #ArrowDx #BiomedicalInnovation

Insulin resistance is a metabolic condition in which the body's cells become less responsive to the effects of insulin, a hormone produced by the pancreas. Insulin plays a crucial role in regulating blood sugar (glucose) levels. When cells become resistant to insulin, they DO NOT respond effectively to its signals, leading to elevated blood sugar levels. Insulin resistance often develops gradually and can be influenced by various factors, including: Obesity, Genetics, Lack of physical activity, Medications, Rare disorders, Type 2 diabetes, PCOS, and Hypertension. 🌐https://bit.ly/3KIFnWj ☎️ San Antonio: 210-982-0320 ☎️ South San Antonio: 210-368-6055 ☎️ Austin: 512-384-1560 ☎️ Georgetown: 737-444-8408 ☎️ Edinburg: 956-284-6353 ☎️ Brownsville: 956-468-3360 . . . #PinnacleClinicalResearch #ClinicalTrials #Research #LiverHealth #Wellness #HealthForAll #HealthyLifestyle #Diabetes #InsulinResistance #Texas #medical #clinical

#kidneydisease #medicine #medicalsciences https://lnkd.in/guYfvukc A new study reports a beneficial effect of avenciguat — a novel, nitric oxide (NO)-independent, soluble guanylate cyclase (sGC) activator — on albuminuria in patients with chronic kidney disease (CKD). These findings were presented at the 61st European Renal Association Congress in Stockholm. In patients with CKD, insufficient production of NO leads to impairment of NO–sGC–cyclic guanosine monophosphate signalling in the kidney, resulting in endothelial dysfunction and an increased risk of disease progression. Avenciguat was developed with the aim of restoring #endothelial #function and thereby slowing loss of kidney function and reducing the risk of cardiovascular disease in patients with CKD.